Overview
Advanced therapies company's Q4 revenue rose 23%, beating analyst expectations
Net income for Q4 increased 17% yr/yr
Company achieved record Q4 gross margin of 79%
Outlook
Vericel forecasts 2026 total revenue between $316 mln and $326 mln
Company expects MACI revenue of $280 mln to $286 mln in 2026
Vericel anticipates gross margin of approximately 75% for 2026
Result Drivers
MACI REVENUE GROWTH - MACI revenue grew 23% in Q4, contributing significantly to total revenue growth
SALES FORCE EXPANSION - Completed MACI sales force expansion, contributing to increased revenue
FACILITY COSTS - Increased operating expenses due to new Burlington facility costs
Company press release: ID:nGNX4Wkb8x
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $92.92 mln | $91.12 mln (7 Analysts) |
Q4 EPS | $0.45 | ||
Q4 Net Income | $23.24 mln | ||
Q4 Adjusted EBITDA | $37.30 mln | ||
Q4 Gross Margin | 79.00% | ||
Q4 Adjusted EBITDA Margin | 40.00% | ||
Q4 Gross Profit | $73.13 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Vericel Corp is $56.50, about 52.3% above its February 25 closing price of $37.09
The stock recently traded at 67 times the next 12-month earnings vs. a P/E of 63 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)